Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Technology
History
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/61/40/19/6140199a-8721-a172-b247-eb9989975be9/mza_18046110378092382110.jpg/600x600bb.jpg
AUAUniversity
American Urological Association
410 episodes
1 day ago
AUA2025: Key Takeaways: Lower Urinary Tract Reconstruction Presenters: George E. Koch, MD & Kurt A. McCammon, MD, FACS
Show more...
Education
RSS
All content for AUAUniversity is the property of American Urological Association and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
AUA2025: Key Takeaways: Lower Urinary Tract Reconstruction Presenters: George E. Koch, MD & Kurt A. McCammon, MD, FACS
Show more...
Education
https://i1.sndcdn.com/artworks-SXIPgznUenbFy8zc-o4dVVg-t3000x3000.png
The Latest Breakthroughs in LG-IR-NMIBC (2025)
AUAUniversity
1 hour 12 minutes 29 seconds
1 month ago
The Latest Breakthroughs in LG-IR-NMIBC (2025)
The Latest Breakthroughs in LG-IR-NMIBC (2025) CME Available: auau.auanet.org/node/43689 After participating in this CME activity, participants will be able to: 1. Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes. 2. Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns. 3. Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments. 4. Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval). 5. Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies. 6. Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery. ACKNOWLEDGEMENTS Support provided by an independent educational grant from: UroGen Pharma, Inc.
AUAUniversity
AUA2025: Key Takeaways: Lower Urinary Tract Reconstruction Presenters: George E. Koch, MD & Kurt A. McCammon, MD, FACS